Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · May 2015
Review Meta AnalysisTong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention.
Percutaneous coronary intervention (PCI) is a standard treatment for coronary heart disease (CHD). Restenosis, defined as a 50% reduction in luminal diameter at six months after PCI, indicates a need for revascularisation. Restenosis has proven to be a major drawback to PCI. Tong-xin-luo is one of the prophylactic strategies for cardiovascular events in patients after PCI that is widely used in China, but its efficacy and safety have not been systematically evaluated. ⋯ The addition of Tong-xin-luo to conventional Western medicine may possibly prevent restenosis and recurrence of cardiovascular events in patients with CHD after PCI. However, the data are limited by publication bias and high risk of bias for included studies. Further high-quality trials are required to evaluate the potential effects of this intervention.
-
Cochrane Db Syst Rev · May 2015
Review Meta AnalysisWITHDRAWN: Arthroplasty versus fusion in single-level cervical degenerative disc disease.
This review was withdrawn due to non‐compliance with the Cochrane Commercial Sponsorship Policy. It has been replaced by Arthroplasty versus fusion for single‐level cervical degenerative disc disease. The editorial group responsible for this previously published document have withdrawn it from publication.
-
Cochrane Db Syst Rev · May 2015
Review Meta AnalysisWITHDRAWN: Botulinum toxin for subacute/chronic neck pain.
Withdrawn due to non‐compliance with The Cochrane Collaboration’s Commercial Sponsorship Policy The editorial group responsible for this previously published document have withdrawn it from publication.
-
Cochrane Db Syst Rev · May 2015
Review Meta Analysis Comparative StudyHaemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
Convective dialysis modalities (haemofiltration (HF), haemodiafiltration (HDF), and acetate-free biofiltration (AFB)) removed excess body fluid across the dialysis membrane with positive pressure and accumulated middle- and larger-size accumulated solutes more efficiently than haemodialysis (HD). This increased larger solute removal combined with use of ultra-pure dialysis fluid in convective dialysis is hypothesised to reduce the frequency and severity of symptoms during dialysis as well as improve clinical outcomes. Convective dialysis therapies (HDF and HF) are associated with lower mortality compared to diffusive therapy (HD) in observational studies. This is an update of a review first published in 2006. ⋯ Convective dialysis may reduce cardiovascular but not all-cause mortality and effects on nonfatal cardiovascular events and hospitalisation are inconclusive. However, any treatment benefits of convective dialysis on all patient outcomes including cardiovascular death are unreliable due to limitations in study methods and reporting. Future studies which assess treatment effects of convection dose on patient outcomes including mortality and cardiovascular events would be informative.
-
Cochrane Db Syst Rev · May 2015
Review Meta AnalysisNegative pressure wound therapy for treating pressure ulcers.
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both. Negative pressure wound therapy (NPWT) is a treatment option for pressure ulcers; a clear, current overview of the evidence is required to facilitate decision-making regarding its use. ⋯ There is currently no rigorous RCT evidence available regarding the effects of NPWT compared with alternatives for the treatment of pressure ulcers. High uncertainty remains about the potential benefits or harms, or both, of using this treatment for pressure ulcer management.